These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31957067)

  • 1. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Baumann T; Montserrat E
    Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
    Molica S; Baumann T; Giannarelli D
    Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
    Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
    Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
    Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
    Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
    Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 13. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
    Timofeeva N; Gandhi V
    Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aspergillus spondylodiscitis in a patient treated with ibrutinib].
    Petitdemange A; Martin A; Ruch Y; Chatron E; Karol A; Hansmann Y
    Med Mal Infect; 2020 May; 50(3):296-297. PubMed ID: 31722863
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
    Rigolin GM; Del Giudice I; Bardi A; Melandri A; García-Jacobo RE; Cura F; Raponi S; Ilari C; Cafforio L; Piciocchi A; Arena V; Reda G; Albano F; Molica S; Sportoletti P; Trentin L; Marchetti M; Nanni M; Peragine N; Mariglia P; Vignetti M; Guarini A; Mauro FR; Foà R; Cuneo A
    Blood; 2021 Dec; 138(25):2727-2730. PubMed ID: 34587233
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.
    Visentin A; Imbergamo S; Trimarco V; Pravato S; Romano Gargarella L; Frezzato F; Scapinello G; Bertorelle R; Piva E; Facco M; Semenzato G; Piazza F; Trentin L
    Hematol Oncol; 2020 Dec; 38(5):823-826. PubMed ID: 32979282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Vigna E; Martino EA; Mendicino F; Botta C; Caracciolo D; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
    Am J Hematol; 2021 May; 96(5):E168-E171. PubMed ID: 33580969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.